Project description
A better-tolerated treatment for myeloid leukaemia
Acute myeloid leukaemia (AML) is a haematological malignancy with poor outcome. Current treatment options entail chemotherapy followed by allogeneic haematopoietic stem cell transplantation. However, most patients relapse, necessitating the development of more targeted and better-tolerated treatments. To address this unmet problem, the EU-funded LapIt project has developed a novel drug that targets a specific AML biomarker associated with poor prognosis. The idea is to conjugate the drug with an antibody against the interleukin-7 receptor that is overexpressed in AML cells. This is expected to improve the efficiency of drug targeting and minimise associated toxicity.
Objective
Acute Myeloid Leukemia (AML), a cancer of the myeloid line of blood cells, is the most common type of leukemia in adults (~350.000 new cases yearly worldwide), yet continues to have the lowest overall survival rate of all leukemias (26.9%). The disease is characterized by clonal expansion of undifferentiated myeloid precursors, leading to anomalous hematopoiesis and bone marrow failure. Current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) with treatment costs up to €300k per patient. Although some AML patients respond to chemotherapy and HSCT, most patients that go into remission show disease relapse (up to and 70%). In addition, minimal advances have been made for patients unable to tolerate intensive treatment, mostly representing older patients. This presses the need for new AML treatments that are (1) more effective and (2) tolerated by all patients. In LapIt, we will further develop a novel treatment strategy for AML, based on targeting a macromolecular target that is marker of poor prognosis for AML patients with the drug Lap. Importantly, to guarantee specific uptake of Lap by AML cells and minimize side effects to healthy cells, the drug will be further developed as an antibody-drug conjugate targeting a validated receptor which is overexpressed in AML and other leukemias. As such, our drug will not only be more effective than currently used AML therapies, but will also be tolerated by patients unable to tolerate intensive treatments. With our proposed drug candidate we are able to make, for the first time, AML treatment a clinical reality for any AML patient.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinetransplantation
- medical and health sciencesclinical medicineoncologyleukemia
You need to log in or register to use this function
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
CB2 1TN Cambridge
United Kingdom